AN ENIGMA. That is how Clinuvel chief executive Philippe Wolgen describes the biotechnology company he heads. It’s an unusual description for what is one of Australia’s top 500 companies, with market capitalisation of nearly $230 million. Or for one with a share price that has almost quadrupled in the past five years.But French-born Wolgen, 44, is referring to the drug that Clinuvel has developed, more than to the company itself.
